High-grade astrocytoma treated concomitantly with estramustine and radiotherapy.
2006 (English)In: J Neurooncol, ISSN 0167-594X, Vol. 78, no 3, 321-6 p.Article in journal (Refereed) Published
OBJECTIVES: The presence of numerous mast cells or eosinophils in Hodgkin lymphoma (HL) tumours have both been described as negative prognostic factors. One cytokine related to HL is interleukin-9 (IL-9) and it is known to affect both mast cells and eosinophils. The aim of this study was to explore if the expression of IL-9 correlates to the presence of these inflammatory cells in HL tumours. METHODS: In 131 HL biopsies, immunostainings for IL-9 and IL-9 receptor (IL-9R) were performed. The same material was previously stained for mast cells and eosinophils. These data were correlated to clinical and survival data from all patients. RESULTS: Fifty-three percent of cases were positive for IL-9 and 19% were positive for IL-9R in the cytoplasm of the tumour cells. The IL-9 positive patients had more eosinophils (P = 0.002) and mast cells (P = 0.02) in their tumours, more often a nodular sclerosis histology (P < 0.0001), a higher white-blood-cell count (P = 0.006) and a higher erythrocyte sedimentation rate (P = 0.003) at the time of diagnosis. CONCLUSIONS: IL-9 expression is related to the histology, clinical picture and the presence of eosinophils and mast cells in HL. These results indicate that IL-9 is an important part of the cytokine network and inflammatory infiltrate in HL.
Place, publisher, year, edition, pages
2006. Vol. 78, no 3, 321-6 p.
Adult, Aged, Aged; 80 and over, Antineoplastic Agents; Alkylating/*administration & dosage, Astrocytoma/*drug therapy/*radiotherapy, Brain Neoplasms/*drug therapy/*radiotherapy, Combined Modality Therapy, Estramustine/*administration & dosage, Female, Humans, Male, Middle Aged, Quality of Life, Radiotherapy Dosage, Severity of Illness Index, Survival Analysis, Treatment Outcome
IdentifiersURN: urn:nbn:se:uu:diva-25116PubMedID: 16598426OAI: oai:DiVA.org:uu-25116DiVA: diva2:52890